Tumors regress under high amounts of IFN-γ through apoptosis and ferroptosis (18) and recombinant IFN-γ therapy against adult T-cell leukemia is approved in Japan (19). The gene discussed is IFNG; the disease is adult T-cell leukemia/lymphoma.